Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Skrypkina, Inessa ^a   Tsyba, Liudmyla ^a   Onyshchenko, Kateryna ^a   Morderer, Dmytro ^a   Kashparova, Olena ^a   Nikolaienko, Oleksii ^a   Panasenko, Grigory ^a   Vozianov, Sergii ^b   Romanenko, Alina ^b   Rynditch, Alla ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^b STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CELL FREE DNA; DNA; INTEGRIN ALPHA9BETA1; PROTEIN; PROTEIN FHIT; PROTEIN LRRC3B; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; ACID ANHYDRIDE HYDROLASE; APC PROTEIN, HUMAN; FRAGILE HISTIDINE TRIAD PROTEIN; LRRC3B PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC VALUE; DNA METHYLATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MIDDLE AGED; PROMOTER REGION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; BLOOD; CASE CONTROL STUDY; GENETICS; KIDNEY TUMOR;

ACID ANHYDRIDE HYDROLASES; ADENOMATOUS POLYPOSIS COLI PROTEIN; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84990922467     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/3693096     Document Type: Article

References (80)

1. G. Banumathy and P. Cairns, "Signaling pathways in renal cell carcinoma, " Cancer Biology and Therapy, vol. 10, no. 7, pp. 658-664, 2010.
2. K. Gupta, J. D. Miller, J. Z. Li, M. W. Russell, and C. Charbonneau, "Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review, " Cancer Treatment Reviews, vol. 34, no. 3, pp. 193-205, 2008.
3. Ministry of Healthcare of Ukraine, The Features Diagnosis and Prognosis Factors Renal Cell Carcinoma, Ministry of Healthcare of Ukraine, 2011, http://www. souu. org. ua.
4. World Cancer Research Fund International/American Institute for Cancer Research, Continuous Update Project Report: Diet, Nutrition, Physical Activity and Kidney Cancer, 2015.
5. A. Lopez-Beltran, M. Scarpelli, R. Montironi, and Z. Kirkali, "2004 WHO classification of the renal tumors of the adults, " European Urology, vol. 49, no. 5, pp. 798-805, 2006.
6. P. Hadaczek, Z. Siprashvili, M. Markiewski et al., "Absence or reduction of FHIT expression in most clear cell renal carcinomas, " Cancer Research, vol. 58, no. 14, pp. 2946-2951, 1998.
7. E. Arai and Y. Kanai, "Genetic and epigenetic alterations during renal carcinogenesis, " International Journal of Clinical and Experimental Pathology, vol. 4, no. 1, pp. 58-73, 2011.
8. B. N. Lasseigne, T. C. Burwell, M. A. Patil, D. M. Absher, J. D. Brooks, and R. M. Myers, "DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma, " BMC Medicine, vol. 12, no. 1, article 235, 2014.
9. N. Shenoy, N. Vallumsetla, Y. Zou et al., "Role of DNA methylation in renal cell carcinoma, " Journal ofHematology and Oncology, vol. 8, no. 1, article 88, 2015.
10. G. J. Fournié, J.-P. Courtin, F. Laval et al., "Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours, " Cancer Letters, vol. 91, no. 2, pp. 221-227, 1995.
11. H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, "Cell-free nucleic acids as biomarkers in cancer patients, " Nature Reviews Cancer, vol. 11, no. 6, pp. 426-437, 2011.
12. B. Taback and D. S. B. Hoon, "Circulating nucleic acids and proteomics of plasma/serum: clinical utility, " Annals of the New York Academy of Sciences, vol. 1022, pp. 1-8, 2004.
13. R. Wasserkort, A. Kalmar, G. Valcz et al., "Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island, " BMC Cancer, vol. 13, article 398, 2013.
14. I. Ya. Skrypkina, V. I. Kashuba, V. V. Gordiyuk et al., "Identification of changes in gene loci potentially associated with renal cancer by novel technique of NotI microarrays, " Reports of the National Academy of Sciences of Ukraine, vol. 11, pp. 188-192, 2006.
15. V. I. Kashuba, I. Y. Skrypkina, D. V. Saraev et al., "Identification of changes in gene loci potentially associated with cervical cancer usingNotI microarrays, "Ukrain'skyi Biokhimichnyi Zhurnal, vol. 78, no. 2, pp. 113-120, 2006.
16. V. I. Loginov, D. S. Khodyrev, I. V. Pronina et al., "Methylation of the RASSF1A promoter region and the allelic imbalance frequencies in chromosome 3 critical regions correlate with progression of clear cell renal carcinoma, " Molecular Biology, vol. 43, no. 3, pp. 394-402, 2009.
17. I. Peters, K. Rehmet, N. Wilke et al., "RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis, " Molecular Cancer, vol. 6, article 49, 2007.
18. S. Hauser, T. Zahalka, and G. Fechner, "Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study, " Anticancer Research, vol. 33, pp. 4651-4656, 2013.
19. M. De Martino, T. Klatte, A. Haitel, and M. Marberger, "Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker, " Cancer, vol. 118, no. 1, pp. 82-90, 2012.
20. M. O. Hoque, S. Begum, O. Topaloglu et al., "Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serumDNA of patients with renal cancer, " Cancer Research, vol. 64, no. 15, pp. 5511-5517, 2004.
21. U. Ramp, E. Caliskan, T. Ebert et al., "FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival, " The Journal of Pathology, vol. 196, no. 4, pp. 430-436, 2002.
22. S. Kvasha, V. Gordiyuk, A. Kondratov et al., "Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas, " Cancer Letters, vol. 265, no. 2, pp. 250-257, 2008.
23. L. J. Herrera, S. Raja, W. E. Gooding et al., "Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies, " Clinical Chemistry, vol. 51, no. 1, pp. 113-118, 2005.
24. D. Czeiger, G. Shaked, H. Eini et al., "Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer, " American Journal of Clinical Pathology, vol. 135, no. 2, pp. 264-270, 2011.
25. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821-9826, 1996.
26. K. Lo, J. Kwong, A. B. Hui et al., "Advances in brief high frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma, " Journal of Clinical Oncology, pp. 3877-3881, 2001.
27. S. Zöchbauer-Müller, K. M. Fong, A. Maitra et al., "5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer, " Cancer Research, vol. 61, no. 9, pp. 3581-3585, 2001.
28. M. Shinozaki, D. S. B. Hoon, A. E. Giuliano et al., "Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis, " Clinical Cancer Research, vol. 11, no. 6, pp. 2156-2162, 2005.
29. A. G. Kondratov, L. A. Stoliar, S. M. Kvasha et al., "Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas, " Molecular Medicine Reports, vol. 5, no. 2, pp. 509-512, 2012.
30. T. Kuroki, F. Trapasso, S. Yendamuri et al., "Allele loss and promoter hypermethylation of VHL, RAR-α, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma, " Cancer Research, vol. 63, no. 13, pp. 3724-3728, 2003.
31. J.-L. Li, Q. Fei, J. Yu, H.-Y. Zhang, P. Wang, and J. De Zhu, "Correlation between methylation profile of promoter cpg islands of sevenmetastasis-Associated genes and their expression states in six cell lines of liver origin, " Ai Zheng, vol. 23, no. 9, pp. 985-991, 2004.
32. S. Bhalerao and P. Kadam, "Sample size calculation, " International Journal of Ayurveda Research, vol. 1, no. 1, pp. 55-57, 2010.
33. E. Heitzer, P. Ulz, and J. B. Geigl, "Circulating tumor DNA as a liquid biopsy for cancer, " Clinical Chemistry, vol. 61, no. 1, pp. 112-123, 2015.
34. C. Roth, K. Pantel, V. Müller et al., "Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression, " BMC Cancer, vol. 11, no. 1, article 4, 2011.
35. S. Sai, D. Ichikawa, H. Tomita et al., "Quantification of plasma cell-free DNA in patients with gastric cancer, " Anticancer Research, vol. 27, no. 4, pp. 2747-2751, 2007.
36. T.-L. Wu, D. Zhang, J.-H. Chia, K.-C. Tsao, C.-F. Sun, and J. T. Wu, "Cell-free DNA: measurement in various carcinomas and establishment of normal reference range, " Clinica Chimica Acta, vol. 321, no. 1-2, pp. 77-87, 2002.
37. C. Bettegowda, M. Sausen, R. J. Leary et al., "Detection of circulating tumor DNA in early-And late-stage human malignancies, " Science Translational Medicine, vol. 6, no. 224, Article ID 224ra24, 2014.
38. G. Feng, X. Ye, F. Fang, C. Pu, H. Huang, and G. Li, "Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma, " Disease Markers, vol. 34, no. 2, pp. 105-111, 2013.
39. A. Kienel, D. Porres, A. Heidenreich, and D. Pfister, "cfDNA as a prognostic marker of response to taxane based chemotherapy in patients with prostate cancer, "TheJournal ofUrology, vol. 194, no. 4, pp. 966-971, 2015.
40. Z. Chen, A. Fadiel, F. Naftolin, K. D. Eichenbaum, and Y. Xia, "CirculationDNA: biological implications for cancer metastasis and immunology, " Medical Hypotheses, vol. 65, no. 5, pp. 956-961, 2005.
41. K. Jung, M. Fleischhacker, and A. Rabien, "Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature, " Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1611-1624, 2010.
42. A. A. Kamat, F. Z. Bischoff, D. Dang et al., "Circulating cellfree DNA: a novel biomarker for response to therapy in ovarian carcinoma, " Cancer Biology and Therapy, vol. 5, no. 10, pp. 1369-1374, 2006.
43. C. Cheng, M. Omura-Minamisawa, Y. Kang, T. Hara, I. Koike, and T. Inoue, "Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy, " Cancer Science, vol. 100, no. 2, pp. 303-309, 2009.
44. A. R. Thierry, F. Mouliere, C. Gongora et al., "Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts, " Nucleic Acids Research, vol. 38, no. 18, pp. 6159-6175, 2010.
45. F. Mouliere, B. Robert, E. Peyrotte et al., "High fragmentation characterizes tumour-derived circulating DNA, " PLoS ONE, vol. 6, no. 9, Article ID e23418, 2011.
46. P. Pinzani, F. Salvianti, S. Zaccara et al., "Circulating cellfree DNA in plasma of melanoma patients: qualitative and quantitative considerations, " Clinica Chimica Acta, vol. 412, no. 23-24, pp. 2141-2145, 2011.
47. H. Lu, J. Busch, M. Jung et al., "Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients, " Clinica Chimica Acta, vol. 452, pp. 109-119, 2016.
48. S. Hauser, T. Zahalka, J. Ellinger et al., "Cell-free circulating DNA: diagnostic value in patients with renal cell cancer, " Anticancer Research, vol. 30, no. 7, pp. 2785-2789, 2010.
49. J. Wan, L. Zhu, Z. Jiang, and K. Cheng, "Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma, " Urologia Internationalis, vol. 91, no. 3, pp. 273-278, 2013.
50. M. Fleischhacker and B. Schmidt, "Circulating nucleic acids (CNAs) and cancer-A survey, " Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol. 1775, no. 1, pp. 181-232, 2007.
51. V. V. Levenson, "DNA methylation as a universal biomarker, " Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 481-488, 2010.
52. A. M. Dworkin, T. H.-M. Huang, and A. E. Toland, "Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment, " Seminars in Cancer Biology, vol. 19, no. 3, pp. 165-171, 2009.
53. M. O. Hoque, "DNA methylation changes in prostate cancer: current developments and future clinical implementation, " Expert Review of Molecular Diagnostics, vol. 9, no. 3, pp. 243-257, 2009.
54. K. Warton and G. Samimi, "Methylation of cell-free circulating DNA in the diagnosis of cancer, " Frontiers in Molecular Biosciences, vol. 2, article 13, 2015.
55. P. P. Anglim, T. A. Alonzo, and I. A. Laird-Offringa, "DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update, " Molecular Cancer, vol. 7, article 81, 2008.
56. Y. Delpu, P. Cordelier, W. C. Cho, and J. Torrisani, "DNA methylation and cancer diagnosis, " International Journal of Molecular Sciences, vol. 14, no. 7, pp. 15029-15058, 2013.
57. J. Charlton, R. D. Williams, M. Weeks et al., "Methylome analysis identifies aWilms tumor epigenetic biomarker detectable in blood, " Genome Biology, vol. 15, no. 8, article 434, 2014.
58. T. C. Brown, C. C. Juhlin, J. M. Healy, M. L. Prasad, R. Korah, and T. Carling, "Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis, " JAMA Surgery, vol. 149, no. 11, pp. 1146-1152, 2014.
59. M. K. Joo, K. H. Kim, J.-J. Park et al., "CpG island promoter hypermethylation of Ras association domain family 1A gene contributes to gastric carcinogenesis, " Molecular Medicine Reports, vol. 11, no. 4, pp. 3039-3046, 2015.
60. X.-M. Wu, Y. Chen, Y. Shao, X.-L. Zhou, and W.-R. Tang, "Association between cigarette smoking and RASSF1A gene promoter hypermethylation in lung cancer patients: a metaanalysis, " Asian Pacific Journal of Cancer Prevention, vol. 15, no. 19, pp. 8451-8454, 2014.
61. H.-L. Wang, P. Liu, P.-Y. Zhou, and Y. Zhang, "Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-Analysis of cohort studies, " Annals of Human Genetics, vol. 78, no. 3, pp. 208-216, 2014.
62. J.-G. Si, Y.-Y. Su, Y.-H. Han, and R.-H. Chen, "Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-Analysis, " Genetic Testing and Molecular Biomarkers, vol. 18, no. 6, pp. 394-402, 2014.
63. K. Daniunaite, S. Jarmalaite, N. Kalinauskaite et al., "Prognostic value of RASSF1 promoter methylation in prostate cancer, " The Journal of Urology, vol. 192, no. 6, pp. 1849-1855, 2014.
64. H. Shi, Y. Li, X. Wang et al., "Association between RASSF1A promoter methylation and ovarian cancer: a meta-Analysis, " PLoS ONE, vol. 8, no. 10, Article IDe76787, 2013.
65. M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon, "Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) inmalignant cutaneousmelanoma, " Cancer Research, vol. 63, no. 7, pp. 1639-1643, 2003.
66. J. Ellinger, D. Holl, P. Nuhn et al., "DNA hypermethylation in papillary renal cell carcinoma, " BJU International, vol. 107, no. 4, pp. 664-669, 2011.
67. V. V. Gordiyuk, G. V. Gerashchenko, I. Y. Skrypkina et al., "Identification of chromosome 3 epigenetic and genetic abnormalities and gene expression changes in ovarian cancer, " Biopolymers and Cell, vol. 24, no. 4, pp. 323-332, 2008.
68. G. V. Gerashchenko, V. V. Gordiyuk, I. Y. Skrypkina et al., "Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer, " Ukrainski Biokhimicheski Zhurnal, vol. 81, no. 4, pp. 81-87, 2009.
69. M. Kim, J.-H. Kim, H.-R. Jang et al., "LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer, " Cancer Research, vol. 68, no. 17, pp. 7147-7155, 2008.
70. A. G. Kondratov, K. A. Nekrasov, L. V. Lototska et al., "Comparative analysis of epigenetic markers in plasma and tissue of patients with colorectal cancer, " Biopolymers and Cell, vol. 30, no. 2, pp. 129-134, 2014.
71. S. Demokan, A. Y. Chuang, K. M. Pattani, D. Sidransky, W. Koch, and J. A. Califano, "Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer, " Oncology Reports, vol. 31, no. 2, pp. 1014-1020, 2014.
72. Y. Takada, X. Ye, and S. Simon, "Theintegrins, " Genome Biology, vol. 8, no. 5, article 215, 2007.
73. A. Mambole, S. Bigot, D. Baruch, P. Lesavre, and L. Halbwachs-Mecarelli, "Human neutrophil integrin α9β1: up-regulation by cell activation and synergy with β2 integrins during adhesion to endothelium under flow, " Journal of Leukocyte Biology, vol. 88, no. 2, pp. 321-327, 2010.
74. D. G. Stupack and D. A. Cheresh, "Integrins and angiogenesis, " Current Topics in Developmental Biology, vol. 64, pp. 207-238, 2004.
75. R. Rathinam and S. K. Alahari, "Important role of integrins in the cancer biology, " Cancer and Metastasis Reviews, vol. 29, no. 1, pp. 223-237, 2010.
76. A. Ghosh, S. Ghosh, G. P. Maiti et al., "Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance, " Cancer Science, vol. 101, no. 6, pp. 1511-1520, 2010.
77. L. Häkkinen, T. Kainulainen, T. Salo, R. Grenman, and H. Larjava, "Expression of integrin α9 subunit and tenascin in oral leukoplakia, lichen planus, and squamous cell carcinoma, " Oral Diseases, vol. 5, no. 3, pp. 210-217, 1999.
78. S. Roy, L. Bingle, J. F. Marshall et al., "The roleof α9β1 integrin in modulating epithelial cell behaviour, " Journal of Oral Pathology and Medicine, vol. 40, no. 10, pp. 755-761, 2011.
79. A. M. Høye, J. R. Couchman, U. M. Wewer, K. Fukami, and A. Yoneda, "The newcomer in the integrin family: integrin α9 in biology and cancer, " Advances in Biological Regulation, vol. 52, no. 2, pp. 326-339, 2012.
80. S. Mitra, D. M. Indra, N. Bhattacharya et al., "RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance, " Genes Chromosomes and Cancer, vol. 49, no. 2, pp. 155-170, 2010.